Department of Orthopedics, The Second Xiangya Hospital Central South University, Changsha, China.
Xiangya School of Medicine, Central South University, Changsha, China.
Cancer Rep (Hoboken). 2021 Oct;4(5):e1385. doi: 10.1002/cnr2.1385. Epub 2021 Apr 1.
Circular RNA PVT1 (circPVT1) is significantly upregulated in various human cancers and is related to poor clinical outcome of cancer patients. However, the prognostic and clinicopathological value of circPVT1 in diverse human cancers remains controversial and inconclusive.
The objective of our study is to evaluate the prognostic and clinicopathological role of circPVT1 for cancer patients.
PubMed, Embase, Web of Science, and Cochrane Library were searched for eligible studies by October 1, 2020. The correlation between circPVT1 expression, and overall survival (OS) and clinical parameters was assessed by pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analyses, heterogeneity, and publication bias were conducted to further enhance reliability. Twelve studies (1282 patients) were selected for this meta-analysis, including 11 on prognosis and 10 on clinicopathological parameters. Elevated expression of circPVT1 was associated with a worse OS in cancer patients (HR, 2.009; 95% CI, 1.667-2.408, 1.892; P < .001). For clinicopathological value, upregulation of circPVT1 was closely related to poor clinical parameters lymph node metastasis (OR = 2.019; 95% CI, 1.026-3.976; P = .042; I = 77.5%; P = 0.000), late clinical stage (OR = 3.594; 95% CI, 1.828-7.065; P < .001; I = 71.7%; P = 0.001), distant metastasis (OR = 4.598; 95% CI, 1.411-14.988; P = .011; I = 78.1%; P = 0.001), and chemoresistant (OR = 6.400; 95% CI, 2.107-19.441; P = .001; I = 49.6%; P = 0.159).
High expression of circPVT1 is correlated with unfavorable prognosis of cancer patients, indicating that circPVT1 can function as a potential prognostic biomarker in human cancer.
Circular RNA PVT1（circPVT1）在各种人类癌症中显著上调，与癌症患者的不良临床结局相关。然而，circPVT1 在不同人类癌症中的预后和临床病理价值仍存在争议和不确定性。
本研究旨在评估 circPVT1 对癌症患者的预后和临床病理作用。
通过检索 PubMed、Embase、Web of Science 和 Cochrane Library，截至 2020 年 10 月 1 日，纳入了符合条件的研究。通过合并风险比（HRs）和优势比（ORs）及其 95%置信区间（CIs）评估 circPVT1 表达与总生存期（OS）和临床参数之间的相关性。进行了亚组分析、异质性和发表偏倚分析，以进一步提高可靠性。共纳入 12 项研究（1282 例患者）进行荟萃分析，其中 11 项研究评估了预后，10 项研究评估了临床病理参数。circPVT1 高表达与癌症患者的 OS 较差相关（HR，2.009；95%CI，1.667-2.408，1.892；P<0.001）。在临床病理价值方面，circPVT1 的上调与不良的临床参数密切相关，包括淋巴结转移（OR=2.019；95%CI，1.026-3.976；P=0.042；I=77.5%；P=0.000）、晚期临床分期（OR=3.594；95%CI，1.828-7.065；P<0.001；I=71.7%；P=0.001）、远处转移（OR=4.598；95%CI，1.411-14.988；P=0.011；I=78.1%；P=0.001）和化疗耐药（OR=6.400；95%CI，2.107-19.441；P=0.001；I=49.6%；P=0.159）。
circPVT1 的高表达与癌症患者的不良预后相关，表明 circPVT1 可作为人类癌症潜在的预后生物标志物。
